Provention Bio, Inc. (PRVB)
(Delayed Data from NSDQ)
$3.98 USD
+0.18 (4.74%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.98 USD
+0.18 (4.74%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.
Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Sanofi (SNY) Surpass Estimates This Earnings Season?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.
Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
by Zacks Equity Research
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.
Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions
by Ethan Feller
Last week ended on a hectic note...
Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)
by Zacks Equity Research
Provention Bio, Inc. (PRVB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset
by Zacks Equity Research
Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 26.09% and 13.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
by Zacks Equity Research
Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?
by Zacks Equity Research
Provention Bio, Inc. (PRVB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Provention Bio, Inc. (PRVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 187.1% in Provention Bio, Inc. (PRVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 8.51% and -81.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 9.80% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Provention Bio (PRVB) Stock Options
by Aditi Saraogi
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Implied Volatility Surging for Provention Bio (PRVB) Stock Options
by Aditi Saraogi
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Provention Bio (PRVB) Stock?
by Zacks Equity Research
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.